Prophylaxis of Complications of Basic Therapy Using Naderin in Socially Significant Diseases

Rationale Standard treatments for malignant neoplasms, tuberculosis, and hepatitis C may be associated with clinically important complications (e.g., cytopenias, immunosuppression, infections) that can impair treatment delivery and rehabilitation. Naderin (sodium nucleinate) was evaluated as an adjunct immunomodulatory/supportive-care approach intended to improve tolerance of basic therapy and reduce complication-related disruptions.

Study Design and Setting This was a prospective, controlled, open-label interventional study conducted at clinical sites affiliated with the Kazakh National Medical University (KazNMU), Almaty, Kazakhstan, supported by KazNMU Grant 2013. Allocation to intervention vs control was non-randomized (controlled cohort comparison).

Study Population and Groups (high-level)

A total of 75 participants with one of the following diagnostic categories were enrolled: malignant neoplasms, tuberculosis, or hepatitis C. Participants were assigned to:

* Intervention group: standard-of-care therapy for the underlying condition plus Naderin (immunocorrection).
* Control group: standard-of-care therapy without Naderin. (Condition-specific eligibility criteria and any stratification by disease category should be presented in the Eligibility Criteria and Study Design/Arms sections rather than repeated here.) Intervention (high-level description) Participants in the intervention group received Naderin (sodium nucleinate) as an adjunct to standard therapy. Key intervention specifications should be captured in the Arms/Interventions module (and/or here if not elsewhere): route, dose, frequency, timing relative to basic therapy, duration, and criteria for dose modification/discontinuation, consistent with protocol reporting standards for reproducibility 1.

Assessments and Follow-up

Participants underwent baseline and follow-up assessments during the active treatment/rehabilitation period that included:

* Hematology monitoring (e.g., WBC and lymphocyte counts; other CBC indices as applicable to the disease group and therapy).
* Clinical surveillance for infectious complications using predefined clinical criteria and documentation of antimicrobial treatment/hospitalization where relevant.
* Documentation of basic-therapy delivery (e.g., interruptions, delays, or discontinuation attributable to complications).
* Safety monitoring for adverse events temporally associated with adjunctive Naderin and with underlying disease therapy.

Outcomes (high-level; details elsewhere) The study evaluated hematologic parameters, infectious complications, treatment delivery disruption due to complications, and rehabilitation-related clinical outcomes. Outcome definitions, metrics, and time frames should be specified in the dedicated Outcome Measures section per SPIRIT guidance 1 and SPIRIT-Outcomes extension expectations for prespecification 2.

Statistical Approach (high-level) Between-group comparisons were planned using appropriate tests based on outcome type (categorical vs continuous) with a prespecified two-sided significance threshold. If subgroup analyses by disease category (neoplasm vs TB vs HCV) were planned, the analysis set and handling of multiplicity should be stated in the Statistical Analysis Plan or briefly here with a reference, consistent with SPIRIT expectations 1.

Ethics and Oversight The study received ethics approval from the Local Ethics Committee of KazNMU (Approval No. 15678). Written informed consent was obtained prior to enrollment. No data monitoring committee was constituted.

• Naderin (Drug), also known as sodium nucleinate: Naderin (sodium nucleinate) is an immunomodulatory agent administered as an adjunct to standard basic therapy for the prophylaxis of complications. It enhances immune function, reduces the duration of neutropenia, and attenuates the decline in hematological parameters during chemotherapy and other aggressive therapies.
• Standard Therapy (Other): Standard basic therapy according to clinical protocols for malignant neoplasms, tuberculosis, and hepatitis C. Includes chemotherapy, anti-tuberculosis therapy, and antiviral therapy as per national guidelines.

Primary outcomes

• Incidence of Infectious Complications [Up to 6 months (from study start to completion)]: The number and proportion of participants who developed infectious complications (e.g., pneumonia, febrile neutropenia, bacterial infections) during the course of basic therapy (chemotherapy, anti-tuberculosis therapy, antiviral therapy).
• Duration of Neutropenia [Up to 6 months (from study start to completion)]: The number of days participants experienced neutropenia (absolute neutrophil count < 1.0 × 10⁹/L) during the course of basic therapy.
• Change in White Blood Cell (WBC) and Lymphocyte Counts [Baseline and up to 6 months]: The change in white blood cell count (× 10⁹/L) and lymphocyte count (× 10⁹/L) from baseline to post-treatment assessment, comparing the Naderin group and control group.

Secondary outcomes

• Time to Recovery of Hematological Parameters [Up to 6 months]: The number of days required for normalization of white blood cell count, lymphocyte count, and absolute neutrophil count after the completion of therapy.
• Adverse Events Profile [Up to 6 months]: The number and severity of adverse events (graded according to CTCAE criteria) experienced by participants in both groups.
• Duration of Hospitalization [Up to 6 months]: The total number of days participants were hospitalized during the course of therapy and follow-up

Sex: All, ages: 18 Years to 50 Years

Inclusion Criteria:

* Diagnosis of malignant neoplasm, tuberculosis, or hepatitis C (confirmed by clinical, laboratory, and/or histopathological criteria)
* Age between 18 and 50 years at the time of enrollment
* Receiving standard basic therapy (chemotherapy, anti-tuberculosis therapy, or antiviral therapy) according to national clinical protocols
* Signed informed consent to participate in the study
* Willingness to comply with study procedures and follow-up visits
* ECOG performance status ≤ 2 or equivalent

Exclusion Criteria:

* Severe concomitant diseases (e.g., decompensated cardiovascular, renal, or hepatic failure) that could interfere with study participation or outcome assessment
* Known hypersensitivity or contraindications to Naderin (sodium nucleinate) or its components
* Pregnancy or lactation
* Participation in any other interventional clinical trial within 30 days prior to enrollment
* Active or uncontrolled infections (other than the primary study condition)
* Severe immunodeficiency (e.g., HIV/AIDS, advanced hematological malignancies) not related to the primary study condition
* Mental or cognitive impairment that would preclude informed consent or compliance with study procedures
* History of organ transplantation requiring immunosuppressive therapy
* Any other condition that, in the investigator's opinion, would make the participant unsuitable for the study